Showing results (571-580 of 610) with videos related to

Sort By:
Pageof 61
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
The Lancet. Oncology|September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
A (Sub)field Guide to Quality Control in Hippocampal Subfield Segmentation on Highresolution T2-weighted MRIK L Canada, N Mazloum-Farzaghi, G Rådman, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
NPJ Precision Oncology|June 7, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumorChristopher Alvarez-Breckenridge, Julie J Miller, Naema Nayyar, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50J F Gainor, H Rizvi, E Jimenez Aguilar, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery|August 17, 2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung CancerAnna F Farago, Beow Y Yeap, Marcello Stanzione, et al.
Pageof 61